Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy

A 40-year-old man presented to our hospital with subacute progressive muscle weakness in the limbs and leukocytosis. Subsequently, the patient was diagnosed with chronic lymphocytic leukemia (CLL) complicated by peripheral motor neuron neuropathy (axonopathy). Serology test for anti-ganglioside GM2 IgG antibody was positive, whereas paraneoplastic syndrome-related and anti-myelin-associated glycoprotein antibodies were not detected. There was no evidence of advanced-stage CLL. Intravenous immunoglobulin and steroid pulse therapy were initiated with slight symptom amelioration. Acalabrutinib and obinutuzumab were administered, and his symptoms gradually improved. Hence, acalabrutinib and obinutuzumab may have been active in patients with CLL complicated by peripheral neuropathy.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2024-11-28
DOI
https://doi.org/10.7759/cureus.74703
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy

Taro Edahiro, Tatsuo Ichinohe, Masahiro Nakamori, Hiroshi Ureshino et al.
1 links
Cureus
Chronic Lymphocytic Leukemia Research
article

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy

Taro Edahiro, Tatsuo Ichinohe, Masahiro Nakamori, Hiroshi Ureshino, Takero Shindo
article en

Abstract

A 40-year-old man presented to our hospital with subacute progressive muscle weakness in the limbs and leukocytosis. Subsequently, the patient was diagnosed with chronic lymphocytic leukemia (CLL) complicated by peripheral motor neuron neuropathy (axonopathy). Serology test for anti-ganglioside GM2 IgG antibody was positive, whereas paraneoplastic syndrome-related and anti-myelin-associated glycoprotein antibodies were not detected. There was no evidence of advanced-stage CLL. Intravenous immunoglobulin and steroid pulse therapy were initiated with slight symptom amelioration. Acalabrutinib and obinutuzumab were administered, and his symptoms gradually improved. Hence, acalabrutinib and obinutuzumab may have been active in patients with CLL complicated by peripheral neuropathy.

CureusVol. 16(11)
Hiroshima University (JP), Hiroshima University Hospital (JP)
Zero hunger
Openalex Percentile: Top 61%
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Acalabrutinib and Obinutuzumab for Chronic Lymphocytic Leukemia Complicated With Peripheral Neuropathy — Taro Edahiro, Tatsuo Ichinohe, et al. · Cureus (2024) | TGRS Research Map | TGRS